Beta Bionics, Inc. (BBNX) Dividend History

Beta Bionics, Inc. is a medical device company focused on developing innovative insulin delivery solutions for people with diabetes. It is known for its flagship product, the iLet Bionic Pancreas, an artificial pancreas system designed to automate insulin and glucagon delivery, aiming to improve glucose management and quality of life for users. The company emphasizes blending advanced technology with patient-centered design to address the needs of individuals requiring tight glucose control.

Dividend History

Beta Bionics, Inc. currently does not pay dividends

Company News

Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges

Goldman Sachs is bullish on Dexcom and Insulet, citing their strong positions in the growing diabetes technology market. The firm is neutral on newly listed Beta Bionics, noting its early adoption phase.

Benzinga

Featured Companies: DXCM PODD
Beta Bionics Announces Closing of $234.6 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Beta Bionics, a medical device company, has successfully completed its initial public offering, raising $234.6 million. The company's shares began trading on the Nasdaq under the ticker symbol 'BBNX'.

GlobeNewswire Inc.

Dividend data last updated 06/06/2025 20:19:50 UTC